AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been a major obstacle in the treatment of non-small cell lung cancer (NSCLC) patients. AXL has been reported to mediate EGFR-TKIs. Recently, third generation EGFR-TKI osimertinib has been approved and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Donghwa, Bach, Duc-Hiep, Fan, Yan-Hua, Luu, Thi-Thu-Trang, Hong, Ji-Young, Park, Hyen Joo, Lee, Sang Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494839/
https://www.ncbi.nlm.nih.gov/pubmed/31043587
http://dx.doi.org/10.1038/s41419-019-1601-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494839/
https://www.ncbi.nlm.nih.gov/pubmed/31043587
http://dx.doi.org/10.1038/s41419-019-1601-6

Ejemplares similares